However, PPARα is crucial for promoting fatty acid oxidation and maintaining energy homeostasis, and therefore indiscriminately inhibiting PPARα activity potently promotes obesity and non-alcoholic fatty liver disease (NAFLD), especially among patients with hyperlipidemia who are already suitable for statin therapy [229]. This evidence concerns the gene PPARA and hyperlipidemia.